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Background: Fibroblast growth factor receptor 3 (FGFR3) inhibits growth-plate chondrocyte proliferation and limits
bone elongation. Gain-of-function FGFR3 mutations cause dwarfism, reduced telomerase activity and shorter
telomeres in growth plate chondroyctes suggesting that FGFR3 reduces proliferative capacity, inhibits telomerase,
and enhances senescence. Thyroid hormone (T3) plays a role in cellular maturation of growth plate chondrocytes
and a known target of T3 is FGFR3. The present study addressed whether reduced FGFR3 expression enhanced
telomerase activity, mRNA expression of telomerase reverse transcriptase (TERT) and RNA component of telomerase
(TR), and chondrocyte proliferation, and whether the stimulation of FGFR3 by T3 evoked the opposite response.
Results: Sheep growth-plate proliferative zone chondrocytes were cultured and transfected with siRNA to reduce
FGFR3 expression; FGFR3 siRNA reduced chondrocyte FGFR3 mRNA and protein resulting in greater proliferation
and increased TERT mRNA expression and telomerase activity (p < 0.05). Chondrocytes treated with T3 significantly
enhanced FGFR3 mRNA and protein expression and reduced telomerase activity (p < 0.05); TERT and TR were not
significantly reduced. The action of T3 at the growth plate may be partially mediated through the FGFR3 pathway.
Conclusions: The results suggest that FGFR3 inhibits chondrocyte proliferation by down-regulating TERT expression
and reducing telomerase activity indicating an important role for telomerase in sustaining chondrocyte proliferative
capacity during bone elongation.
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Linear bone growth is a function of the proliferative cap-
acity of the endochondral growth plate and the size of
the hypertrophic cells. Regulators of chondrocyte prolif-
eration greatly influence the rate and extent of long bone
growth and the resulting mature skeletal size [1,2].
Fibroblast growth factor receptor 3 (FGFR3) is a critical
regulator of growth plate chondrocyte function through
its inhibition of proliferation [3,4]. Gain-of-function
mutations in FGFR3 cause severe restriction of skeletal
growth resulting in dwarfism in both mice and humans
[5]. Loss-of-function mutations in sheep FGFR3 cause
skeletal overgrowth through excessive proliferation of
chondrocytes in the growth plate [6,7].* Correspondence: amoberbauer@ucdavis.edu
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reproduction in any medium, provided the orThe inhibitory regulation by FGFR3 and its localized
expression within the growth plate proliferative zone are
unique among the family of four fibroblast growth factor
receptors. The other FGFRs, 1, 2 and 4, promote prolif-
eration and are primarily expressed in the perichon-
drium [8,9]. Evidence also suggests that FGFR1 may
promote differentiation in the hypertrophic growth plate
zone following exit from the proliferative zone [8,9].
Many hormones and growth factors beyond FGFR3
play a role in the function of the growth plate. Early
findings from children pointed to a clear association be-
tween circulating thyroid hormone (T3) and skeletal size
[10]. Thyroid hormone recruits resting zone growth
plate chondrocytes to initiate proliferation but then inhi-
bits further proliferation and induces hypertrophy to ac-
celerate bone aging (reviewed in [11]); it also induces
FGFR3 expression [12]. The inhibitory effects of T3 aretd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the growth plate.
Chondrocytes within the growth plate undergo mul-
tiple rounds of proliferation to effect bone elongation
[13]. Sustained proliferation of cells can lead to chromo-
somal degradation and DNA damage after consecutive
replications unless telomere length is maintained [14].
Telomeres act as protective caps to the chromosomes
and their length is maintained by telomerase, an enzyme
consisting of a reverse transcriptase catalytic subunit
(TERT) and a template RNA subunit (TR) moiety
[15,16]. Several studies using human in vitro models
have also demonstrated a growth-promoting role of
telomerase and TERT that is independent of telomere-
length maintenance [17-19], however this remains con-
troversial [20]. Transfection experiments have shown
that up-regulation of telomerase activity enhances prolif-
eration and immortalizes cells whereas down-regulation
of telomerase eventually leads to a halt in proliferation
following critical telomere erosion [14,21,22].
Growth plate chondrocytes exhibit reduced prolifera-
tive capacity and cellular senescence as animals advance
through puberty [23]. Although the mechanism control-
ling this gradual cessation of proliferation in growth
plate chondrocytes is not well understood, human chon-
drocyte proliferation rates correlate with telomerase
levels and both decline with advancing age [24]. A gain-
of-function FGFR3 mutation in humans is correlated
with reduced growth plate proliferation, shorter telo-
meres, reduced telomerase activity, and down-regulated
TERT suggesting that FGFR3 may directly inhibit tel-
omerase [24]. To determine if FGFR3 down-regulates
telomerase activity, we hypothesized that reducing
FGFR3 expression levels through siRNA would enhance
chondrocyte proliferation, TERT mRNA expression, and
telomerase activity whereas induction of FGFR3 via the
addition of T3 would have the opposite effect demon-
strating coordination between inhibition of proliferation




Costochondral growth plates were grossly excised from
two commercial-bred male lambs at one week of age.
The University of California, Davis Institutional Animal
Use and Care Committee approved the experimental
protocols for this study. For each trial, all dissected
growth plates were digested to release growth plate
chondrocytes as previously described [25] and pooled.
Freed chondrocytes were layered onto a discontinuous
isotonic gradient as described previously with the
1.0578 g/mL density fraction used as the source of the
primary proliferative zone cells [26-28] and plated at200,000 cells/well in 2 mL of Dulbecco’s modified Eagle’s
medium (DMEM)/F12 (Gibco BRL, Grand Island, NY,
USA) containing 5% fetal bovine serum (FBS) (Gibco),
penicillin (100 U/mL) and streptomycin (100 mg/mL)
(JRH Biosciences, Lenexa, KS) in 6 well tissue-culture
plates. In all cultures chondrocytes were 98% viable,
determined by trypan blue exclusion, at time of plating.
After 1 day, the medium was replaced and cells were
incubated for another day in complete media. Mitotic
doubling time of chondrocytes was approximately 1.5
days. Primary growth plate chondrocytes under similar
in vitro culture methods maintain their chondrocyte
morphology and are resistant to dedifferentiation
through 14 passages [25,29]. In the present experiment,
the cells were cultured for approximately one week with
fewer than five mitotic doublings and the chondrocyte
phenotype was confirmed by using ovine specific PCR
primers [30]. Isolated cells expressed type II collagen
mRNA throughout the culture period. The entire pri-
mary chondrocyte isolation procedure and treatments
were repeated at a later time in a replicate of the trial.
For each trial, the experimental unit was culture well
with each treatment replicated in three wells. The data
reported represent the results of the treatment replicates
for the two trials. Notably, a trial effect was not discern-
ible statistically.
siRNA transfection
Proliferative zone chondrocytes were transfected 2 days
post plating with double stranded RNA (dsRNA) oligos
to mediate post-transcriptional degradation of FGFR3
and FGFR2 mRNA. The siRNA oligos (Table 1) were
designed from published mRNA sequences (GenBank:
AY737276; AJ320477) using the Stealth RNAi designer
(Invitrogen, Carlsbad CA). Proliferative zone chondro-
cytes were lipofectamine transfected as per kit instruc-
tions (BLOCK-IT transfection kit; Invitrogen) at a final
concentration of 100 nM dsRNA per well for each oligo
sequence transfected. Untransfected chondrocyte cul-
tures were also used as a ‘baseline’ control to account for
any direct effects of lipofectamine on treated chondro-
cytes. A GFP reporter plasmid (fluorescein-labeled, Invi-
trogen, Carlsbad, CA), cultured in parallel to the treated
chondrocytes, was used as a transfection efficiency con-
trol. After a 24-hour incubation period post-transfection,
transfection efficiency was measured by counting the
proportion of strongly fluorescing cells containing the
GFP reporter plasmid. The proliferative zone chondro-
cyte transfection efficiency for the GFP reporter plasmid
was approximately 68%. A scrambled dsRNA (ScR) was
transfected and used as control cultures for determining
the effect of the targeted FGFR3 siRNA knockdown.
Growth plate proliferative zone chondrocytes also ex-
press minimally FGFR2, a receptor known to promote
Table 1 Oligo sequences and accession numbers
Sequence (5’ to 3’) Strand Accession
siRNA oligos
FGFR3 CAGGUGUCCUUGGAGUCCAGUUCAU Sense AY737276
AUGAACUGGACUCCAAGGACACCUG Anti-sense
FGFR2 GGGAAUAUACGUGCUUGGCGGGUAA Sense AJ320477
UUACCCGCCAAGCACGUAUAUUCCC Anti-sense
Scrambled control (ScR) CAGUGCCUUGGGACUACUGUUGCAU Sense Invitrogen
AUGCAACAGUAGUCCCAAGGCACUG Anti-sense
Real-Time PCR primers
FGFR3 CGCAGGACACCAGGTCTTTG Forward NM 174318.3
cggcTACTCCTTCGACACCTGCG Reverse
TERT CGCTCCTTCCTGCTCTGCTC Forward NM 001046242.1
cggacGATGGTTTCCACGAGTGTC Reverse
TR GCAGACTGGATGGTGGATGG Forward NR 001576.1
cggtaCGCTGTGCTTTTGGTTACG Reverse
Kanamycin resistance - Exogenous Standard AAGCCCACTGCAAGCTACCTG Forward Invitrogen PCRIII vector based amplicon
CGTTTTGGCTATCTGGACAAGGGAAA Reverse
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effects of FGFR2 on proliferation all experimental chon-
drocyte cultures regardless of additional treatments, in-
cluding the ScR control, were subjected to FGFR2
siRNA knockdown (Table 2).Hormonal treatments
Hormonal treatments to enhance FGFR3 expression and
activation were given 1 day post siRNA transfection: the
lipofectamine-dsRNA transfection solution was removed
and replaced with 2 mL/well of complete media contain-
ing the appropriate hormonal treatment. Recombinant
human FGF18 (30 pM, Peprotech, Rocky Hill NJ), an
FGFR3 ligand, was added to all cultures to activate the
receptor [32]. To enhance FGFR3 expression 1 μM tri-
iodothyronine (T3) (SIGMA, St. Louis, MO) was added
to mediate transcriptional up regulation of FGFR3Table 2 Treatments applied to isolated growth plate
proliferative chondrocytes: double stranded RNA (dsRNA)
oligos to mediate post-transcriptional degradation of
FGFR3 (siRNA FGFR3) and FGFR2 mRNA (siRNA FGFR2),
scrambled dsRNA as control, 30 pM recombinant human
FGF18, or 1 μM tri-iodothyronine (T3)
Treatment ScR siRNA T3
siRNA FGFR3 - + -
scrambled dsRNA + - -
thyroid hormone - - +
siRNA FGFR2 + + +
FGF18 + + +mRNA [12]. Chondrocytes from culture wells were har-
vested at 3, 5, and 7 days post siRNA transfection by di-
gestion with 2.5% trypsin (without phenol red, calcium,
or magnesium) (1 ml/well) for 15 min at 5% CO2 and
37°C followed by 3 mg/mL collagenase type II in
DMEM/F12/5% FBS (2 mL/well) for 45 min. Following
digestion, cell aggregates were gently triturated with a
glass pipette, scraped, and collected. The cells were cen-
trifuged at 150 × g to pellet for supernatant removal.
Cells were washed in 1X PBS and centrifuged again and
the cell pellet snap frozen in liquid nitrogen and stored
at −80°C until DNA, RNA, or protein isolation.Isolation and quantification of DNA, RNA, and protein
Thawed cell pellets were mechanically lysed in 50 μl 1X
PBS by trituration through a small bore pipet tip. The
lysate was homogenized using a Qiashredder spin-
column according to manufacturer recommendations
(Qiagen, Germantown, MD). Approximately 10% of the
cell lysate volume was removed, diluted 1:10 in CHAPS
lysis buffer, snap frozen in liquid nitrogen, and stored
at −80°C. DNA, RNA, and protein were isolated from
the remaining aliquot of the cell lysate (All Prep™ kit,
Qiagen, Germantown, MD). A Qubit fluorometer based
Quant-it assay (Invitrogen, Molecular Probes Inc.,
Eugene, OR) was used to determine the DNA, RNA, and
protein concentration of each well sample; all wells were
replicated in triplicate under each treatment. Chondro-
cyte proliferation was determined by quantifying DNA
concentration of chondrocyte cultures at 3, 5, and 7 days
post siRNA transfection [33].
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Culture mRNAs were transcribed to cDNA with the
iScript cDNA synthesis kit (Bio-Rad, Hercules CA) con-
taining oligo d(t) and random-hexamer primers in a
20 μl reaction (4 μl 5X iScript reaction mix, 1 μl iScript
reverse transcriptase, remaining 15 μl water and 500 ng
total RNA) as per the manufacturer’s recommended
protocol. The resulting reaction volume was diluted 1:5
with DEPC water and stored at −20°C.
Fluorescent-reporter specific primers for real-time qPCR
were designed using the Invitrogen online D-Lux designer
(Invitrogen, Carlsbad CA) and published mRNA sequences
for FGFR3, TR and TERT (Table 1, GenBank: NM_174318.3,
NR_001576.1, and NM_001046242.1, respectively). All
real-time qPCR reactions were run in 96-well plates
using UDG-Supermix (Invitrogen, Carlsbad CA). Each
reaction contained 10 μM of each primer (forward and
reverse), and 5 μl diluted cDNA, in a final volume of 50 μl.
Samples were amplified in an MJ Research Chromo 4
Detector (BioRad, Hercules CA) with one cycle of 50°C for
2 min and 95°C for 2 min, followed by 49 cycles of 95°C
for 15 sec, 60°C for 30 sec with a ramp rate of 2°C per sec.
Fluorescence was collected during each plate read immedi-
ately following the annealing period at 60°C.
The C(t) values were quantified in femtograms using a
standard curve equation defined by five serially diluted
concentrations of an exogenous cDNA [19]. In this case,
the exogenous cDNA standard encoded a kanamycin re-
sistance gene [34] originally constructed as a 1000 bp
RNA portion of an Invitrogen pCRII vector. The kana-
mycin resistance standard RNA was reverse transcribed
into cDNA in tandem with the chondrocyte RNA sam-
ples it quantified. The C(t) threshold and baseline defini-
tions were held constant for all replicates of a gene
signal within each experiment.
Telomerase activity detection
A TRAPeze Telomerase Detection Kit (Chemicon
(Millipore), Temecula, CA) was used to determine
telomerase activity in the thawed chondrocyte lysate
samples, using real-time quantitative PCR-based amplifi-
cation of telomeric repeats in an MJ Research Chromo 4
Detector (BioRad, Hercules CA) following the manufac-
turer’s recommended program. The C(t) values were
determined manually by defining the beginning of the
linear phase in the log-based fluorescence and the best
fit of the standard curve. The C(t) values were quantified
in zmoles using a standard curve equation defined by
five serially diluted concentrations of a telomerase sub-
strate included in the kit as a quantitation control.
Western blotting
Equal concentrations of cellular protein isolated as
detailed above were suspended in a Laemmli-relatedsample buffer (ALO, All Prep™ kit, Qiagen, German-
town, MD), incubated at 90°C for 4 min, separated on a
10% SDS-PAGE gel, and transferred to a PVDF mem-
brane (Amersham, GE Healthcare, Piscataway, NJ) by
electroblotting (30 V, 0.12 mA/cm2 overnight). Following
transfer, the PVDF membrane was blocked1 hour in 5%
non-fat dry milk/0.1% Tween in TBS, washed for 10 min
in 0.1% Tween-20 in TBS, and incubated with 5% BSA
and 0.1% Tween-20 in TBS containing either the FGFR3
(0.4 μg/mL, Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, #sc-31162) or GAPDH (0.1 μg/mL, Millipore, Biller-
ica, MA #MAB374) primary antibodies for 2.5 hours
at 4°C. After primary antibody hybridization, the mem-
branes were washed 3 times with 0.1% Tween-20 in TBS
and incubated with a secondary antibody. Immunoblot-
ting was done with horseradish peroxidase-conjugated
anti-rabbit or anti-mouse secondary antibodies (Jackson
ImmunoResearch, West Grove, PA, 0.04 μg/mL, #711-
035-152, #715-035-151) and ECL detection reagents and
film according to manufacturer's instructions (Amer-
sham, GE Healthcare, Piscataway, NJ). Immunoblots
were digitally captured (Alpha InnotechW ChemiIma-
ger™ model 4400) and protein levels were quantified
(Alpha InnotechW Spotdenso software for densitometric
scanning of bands); GAPDH intensities were used as a
loading control and densitometry values adjusted prior
to comparing for treatment effects.
Statistical analyses
For each trial, each treatment was performed in tripli-
cate. The entire trial was replicated using a second prep-
aration of primary chondrocytes. Chondrocyte cell
culture data were analyzed with day, trial, siRNA trans-
fection, and T3 as the main effects using least squares
analysis of variance (ANOVA) to determine statistical
significance (PROC GLM, Procedure General Linear
Model, SAS version 9.1; SAS Institute Inc., Cary, NC).
General linear model analysis of DNA concentration, tel-
omerase activity, mRNA and protein expression levels
included Tukey pairwise comparison tests of treatment
groups. Statistical significance was defined as P < 0.05




Untransfected baseline control chondrocytes were not
significantly different from ScR control treated chondro-
cytes, or chondrocytes treated with vehicle controls, for
the DNA, mRNA, or protein quantity evaluated at all
post transfection days sampled (p > 0.2, data not shown).
At 3 days post transfection, cells treated with FGFR3
siRNA had a 57% reduction in FGFR3 mRNA. There
was a 55% reduction in FGFR3 protein levels relative to
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0.61 ± 0.13 and 1.36 ± 0.34 arbitrary densitometric units,
respectively (p < 0.05, Figure 1). The reduction in FGFR3
mRNA persisted through 7 days post transfection.
In response to T3 treatment, FGFR3 mRNA was
increased (p < 0.05, Figure 1). At 3 and 7 days post trans-
fection, T3 treated cells had increased FGFR3 mRNA
levels relative to cells without T3 exposure of 79.1%, and
61.2%, respectively, FGFR3 protein levels followed the
increase in mRNA: 3.05 ± 0.84 and 1.36 ± 0.34 arbitrary
densitometric units for T3 treated cells relative to ScR
control treated cells, respectively (p < 0.05, Figure 1).
Chondrocyte proliferation
To examine the effects of FGFR3 on chondrocyte prolif-
eration in FGFR3 siRNA treated cells, DNA concentrationFigure 1 FGFR3 siRNA and T3 effects on FGFR3 mRNA and
protein. A) FGFR3 mRNA (femtogram) at 3 (siRNA 3d) and 7 (siRNA
7d) days post siRNA transfection; B) FGFR3 mRNA as a percentage of
untreated control cells in response to T3 treatment at 3 and 7 days
post exposure. Data are presented as mean ± SEM. An asterisk (*)
denotes means differed from control at p < 0.05; † denotes means
differed from control at p < 0.1. C) FGFR3 protein levels at 3 days
post siRNA transfection for FGFR3 siRNA (lane 1), ScR control treated
chondrocytes (lane 2), and T3 treated chondrocytes. The blot image
is representative of the replicate blots performed and greater
amounts of protein were loaded for the FGFR3 siRNA lane to ensure
detectable signal.was used as a measurement of cell number. In prelimin-
ary experiments we established a direct correlation be-
tween cell counts and DNA concentration. Quantifying
DNA concentration has also been shown to be a robust
indicator of cell number [35]. Seven days post FGFR3
siRNA transfection has been shown to be sufficient time
for determining the effects of FGFR3 siRNA on cell pro-
liferation [36]. At 3 and 5 days post siRNA transfection,
there was no significant difference in DNA concentration
between ScR and FGFR3 siRNA, treated chondrocytes
(p > 0.2, Table 3). At day 5, T3 treated chondrocytes had
reduced DNA concentration. However, at 7 days post siRNA
transfection chondrocytes treated with FGFR3 siRNA had
significantly greater DNA concentration (p < 0.05), hence
cell number, relative to the T3 and ScR control treat-
ments with the latter two treatments not differing from
one another (p > 0.2).Telomerase expression and activity
Chondrocytes treated with FGFR3 siRNA had elevated
telomerase activity compared to that detected for control
chondrocytes whereas chondrocytes treated with T3
showed a reduction in telomerase activity relative to
the ScR control at 3 days (p < 0.05). Specifically, FGFR3
siRNA chondrocytes had ~80% more telomerase activity
than ScR chondrocytes, which in turn had more than 3-
fold greater telomerase activity than chondrocytes trea-
ted with T3 at 3 days post siRNA transfection (p < 0.05,
Figure 2). The difference was not maintained at 7 days.
Expression of telomerase subcomponent TERT was
significantly increased in response to siRNA at 3 days
post exposure (1.83 ± 0.27 and 0.85 ± 0.07 femtogram
for siRNA and ScR, respectively; p < 0.05). In contrast,
exposure to T3 did not significantly alter TERT (0.85 ±
0.07 and 0.56 ± 0.24 fg for ScR and T3, respectively;
p = 0.2). Real-time qPCR analysis of TR mRNA levels
showed no difference for the siRNA, ScR control, and
T3 treatments: 244.57 ± 49.40, 262.90 ± 49.40, 250.20 ±
49.40 femtogram, respectively (p = 0.8), on day 3.Table 3 Chondrocyte proliferation as indicated by DNA
concentration (μg/mL) in response to siRNA transfected,
scrambled control (ScR) transfected, or thyroid hormone
(T3) treatment over time
Treatment
ScR siRNA T3
Day 3 13.8 ± 1.9 17.0 ± 1.5 15.7 ± 2.4
Day 5 28.7 ± 0.6 26.3 ± 1.0 15.8 ± 1.0*
Day 7 34.3 ± 1.8 52.9 ± 2.9* 34.2 ± 0.6
* asterisk denotes difference (p < 0.05) between treatment means for a given
day; data are presented as mean ± SEM.
Figure 2 FGFR3 effects on telomerase activity. Proliferative zone
chondrocytes treated with siRNA to reduce FGFR3 and T3 to
increase FGFR3 were compared to ScR controls. Data are presented
as means ± SEM. An asterisk (*) designates that means for a given
day differed from ScR control at p < 0.05. Untransfected chondrocyte
cultures were not significantly different from ScR controls (data
not shown).
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The purpose of the present study was to experimentally
evaluate effects of altered FGFR3 expression on prolif-
eration and telomerase activity in sheep growth plate
chondrocytes. Wild type growth plate chondrocytes were
used in the present study instead of chondrocytes from
FGFR3 loss-of-function mutants to more tightly model
normal physiological conditions. The knockdown level
of approximately 55% achieved in this study has been
previously characterized as sufficient for downstream
effects of other proliferation inhibitor genes such as p53
[37]. By reducing FGFR3 expression through siRNA
transfection, chondrocytes exhibited enhanced proli-
feration when released from FGFR3 mediated growth
inhibition, a finding similar to that seen in human
adenocarcinoma cells [36].
To enhance FGFR3 expression, chondrocytes were
exposed to T3 at doses comparable to published studies
[12,38-41]. Chondrocytes treated with T3 had double the
FGFR3 mRNA levels relative to that detected in con-
trols. Surprisingly, there was no significant sustained ef-
fect of T3 on cell proliferation in response to the
increased FGFR3. Though reduced chondrocyte prolif-
eration was expected upon exposure to T3, studies have
reported that monolayer chondrocyte cultures respond
to T3 treatment with increased maturation rather than
altered proliferation [41]. The T3 effect on chondrocyte
maturation is suggested to be mediated by FGFR3 [12].
In humans with genetically over-expressed FGFR3,
chondrocyte maturation was correlated with reduced tel-
omerase activity [24]. For the present study, T3 was
employed to increase FGFR3 expression within prolifera-
tive zone chondrocytes and resulted in a down regula-
tion of telomerase activity.With differentiation of growth plate chondrocytes, tel-
omerase activity would be expected to decline [24]. The
target for telomerase down-regulation in mammals is
the reverse transcriptase catalytic subunit (TERT)
[15,42]. The proliferative chondrocytes of the present
study showed ubiquitous TR expression and low levels
of TERT mRNA expression in chondrocytes with normal
FGFR3 expression. Reducing FGFR3 increased prolifera-
tion and telomerase activity suggesting that reducing
levels of FGFR3 can increase the activity of telomerase
sufficiently to support the replication of the chondro-
cytes. Ectopic expression of TERT has been shown to
enhance proliferation and immortalize cells in culture
[17-19]. Elevated TERT expression observed with
reduced FGFR3, and lower telomerase levels when chon-
drocytes had elevated FGFR3 in response to T3 suggest
that induction of FGFR3 mediates T3 action as a nega-
tive regulator of telomerase. It must be noted however
that other growth factors are influenced by elevated T3
[10] and the telomerase effects observed may also reflect
the contributions of other factors.
Most somatic cells diminish telomerase activity after
prenatal development and begin a process of gradual
telomere erosion with each replication cycle known as
the “mitotic clock” [15,16]. In contrast, tissues requiring
rapid and continual proliferation maintain telomerase
activity to conserve the integrity of chromosomal struc-
ture through sustained replication events [15,16].
Growth plate chondrocytes have active telomerase [43],
yet exhibit senescence at an earlier age relative to most
somatic cells [23] undergoing only 3 to 5 rounds of mi-
tosis before differentiation and eventual apoptosis [13].
Early senescence and few replicative cycles does not sup-
port the need to maintain chromosomal ends and sus-
tained telomerase activity. This would imply that
telomere maintenance should not be required in prolif-
erative zone chondrocytes. Yet, telomerase activity does
increase with differentiation and progression of chon-
drocytes through the resting, proliferative, and hyper-
trophic zones [24]. Taken together, that would suggest
an alternate role for telomerase within the growth plate
that may involve cellular proliferation [18] as well as
promoting differentiation [24,44].
Telomerase has been shown to increase proliferation
and delay apoptosis in cells [18], whereas FGFR3 pro-
motes apoptosis and cessation of proliferation in the
growth plate [1,45]. In vivo, the presence of a single
functional FGFR3 copy results in enhanced skeletal
growth and delayed maturation [6,7]. Reduced FGFR3
expression may enhance telomerase activity, increase
growth plate chondrocyte proliferation and delay apop-
tosis, thereby enabling greater endochondral bone
growth resulting in a larger mature skeletal size. The
opposite would also be true; thus, pharmaceutical
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to control cancer [46] may impact growth plate function
if given to juveniles. The role of telomerase in both sup-
porting proliferation and then in the subsequent cessa-
tion of proliferation are areas that needs further
exploration and such studies may shed light on the
mechanisms regulating closure of the growth plate.
Conclusions
The present study demonstrated that reduced FGFR3
expression confers increased proliferative capacity on
growth plate chondrocytes through enhanced TERT
levels in vitro and suggests a likely translation to
enhanced overall bone length in vivo. Collectively the
data suggest that normal FGFR3 inhibits cell prolifera-
tion by reducing telomerase through down regulating
TERT expression and telomerase activity, indicating an
important role for telomerase in sustaining chondrocyte
proliferative capacity and rate during bone elongation.
Further, these findings suggest that the action of T3 on
growth plate chondrocyte function may be partially
mediated by FGFR3 and its effects on telomerase. Al-
though regulation of chondrocyte activity as the growth
plate approaches closure is incompletely understood,
results of the present study suggest that FGFR3 may play
a pivotal role.
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